Longaeva Partners

Longaeva Partners LP is a New York-based investment management firm that focuses on creating enduring value for its investors through deep research and forward-thinking insights in the global equity markets. The firm is dedicated to adapting to evolving markets and fostering meaningful partnerships to deliver industry-leading returns. They aim to shape the future of investing by harnessing diverse ideas and transforming challenges into opportunities, driving smarter decisions and lasting impact.

Established in 2024, Longaeva Partners was founded by Peter Goodwin, who serves as the Chief Investment Officer. The firm operates as an internal long/short equities unit within Balyasny Asset Management, exclusively investing Balyasny's assets. This structure allows Longaeva Partners to leverage the resources and expertise of a larger asset management firm while focusing on its specialized investment strategies. The name "Longaeva" is inspired by the longaeva pine, symbolizing longevity, adaptability, and persistence, reflecting the firm's investment philosophy.

Longaeva Partners focuses on investing in companies that develop technologies aimed at extending human lifespan and improving human health. Their investment interests span areas such as biotechnology, artificial intelligence, and regenerative medicine. A notable investment includes participation in a $100 million convertible note financing round for Imperative Care, a medical technology company specializing in treatments for thromboembolic disease.

The team at Longaeva Partners, led by Peter Goodwin, has a proven track record of generating superior returns for investors. Goodwin previously held a top-performing portfolio manager role at Point72 Asset Management before joining Balyasny to build Longaeva Partners. The firm's approach emphasizes rigorous research and a forward-thinking perspective to identify and capitalize on investment opportunities across various sectors.